Astellas company Audentes Therapeutics announced construction of a gene therapy manufacturing plant in Sanford, North Carolina.
A recap of recent managerial promotions and hirings in the biopharma industry.
Indianapolis-based Eli Lilly is adding 462 new jobs in Durham County, North Carolina over five years.
GlaxoSmithKline veteran Richard Saynor is coming home to Sandoz after being named the new chief executive officer of the Novartis subsidiary.
Mumbai-based Glenmark Pharmaceuticals is spinning off its innovation business into a U.S.-based standalone company.
Bay Area-based genomics company 10X Genomics has become one of the fastest growing privately held companies in the region with an earnings increase of more than 2,000 percent over a three-year period. As a result of that growth, the company optioned space in its town of Pleasanton, Calif.
Novo Nordisk is in advanced talks to acquire assets to bolster the company’s struggling biopharma business after the drugmaker announced the hiring of an AstraZeneca executive to head the unit.
Denmark’s Novo Nordisk will cut around 250 jobs in the United States, but the drugmaker will also hire an as-yet undetermined number of staff to new positions.
Astellas Americas has a new VP in its Medical Affairs Oncology therapeutic area, and a new VP and an executive director of promotions in its corporate communications organization.
Jason D. Hanson was appointed president, CEO and director of enGene Inc., a biotechnology company developing novel non-viral vector gene therapies to provide oral delivery of a wide range of protein drugs.